BioSpace News Archive

TLC599 showed locally sustained release profile up to 120 days, dose proportionality, minimal systemic exposure and potential for repeat dosing

Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.

Patients receiving Cosentyx showed no radiographic progression in almost 90% of PsA patients over two years. Of the patients receiving the drug at 150 mg, 66.3% had rapid and significant improvements in symptoms of the disease with axial manifestations at week 12.

The funds raised will take the company through the end of 2020. The company plans to have a product on the market in 2021, if all goes well.

Probiodrug AG, announced that with entry into the commercial register Stendal the Company has now officially changed its name to Vivoryon Therapeutics AG as of June 11, 2019.

BIO’s Jim Greenwood hailed the executive order as an important decision to foster biology-driven solutions to nutrition and improving crop yield.

Novartis was alleged to have held about 80,000 sham events where doctors were wined and dined in order to boost sales of key medications.

ODDO SEYDLER BANK AG will henceforth be the second Designated Sponsor of Expedeon AG’s share, as Expedeon announced.

The indictment revolves around several investment projects including the development of a biotech company, AnC Bio Vermont, in Newport, Vermont, and the government’s EB-5 program, which offers permanent U.S. residency in exchange for $500,000 investments in approved businesses that will create specific numbers of jobs.

The new LaunchLabs incubator program is expected to open in 2020. This is the second incubator program Columbia University has become involved with this month.